Roy Pettipher
Fundador en Orca Pharmaceuticals Ltd. .
Perfil
Roy Pettipher is the founder of Orca Pharmaceuticals Ltd.
which was founded in 2012, where he holds the title of Chief Scientific Officer.
He is currently working as a Research Director at Atopix Therapeutics Ltd.
Dr. Pettipher's former positions include Pharmacology Director at Oxagen Ltd., Principal at Pfizer Inc., and Principal at Wellcome Plc.
Cargos activos de Roy Pettipher
Empresas | Cargo | Inicio |
---|---|---|
Orca Pharmaceuticals Ltd.
Orca Pharmaceuticals Ltd. BiotechnologyHealth Technology Orca Pharmaceuticals Ltd. operates as a biotechnology company that develops oral drugs for the treatment of chronic inflammatory diseases. It also develops oral drug for the treatment a spectrum of autoimmune diseases that includes psoriasis, ankylosing spondylitis and inflammatory bowel disease. The company was founded by Michael Hunter, Roy Pettipher, Dan Littman, and Jun R. Huh in 2012 and is headquartered in Abingdon, the United Kingdom. | Fundador | 01/01/2012 |
Atopix Therapeutics Ltd.
Atopix Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Atopix Therapeutics Ltd. develops medicines to treat atopic dermatitis and severe asthma. The firm also assess the safety and pharmacokinetic profile of its back-up molecule ATX2417 in a phase I study. The company was incorporated on October 10, 2012 and is headquartered in Abingdon, the United Kingdom. | Director Técnico/Científico/I+D | - |
Antiguos cargos conocidos de Roy Pettipher.
Empresas | Cargo | Fin |
---|---|---|
PFIZER, INC. | Corporate Officer/Principal | - |
Wellcome Plc
Wellcome Plc Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Wellcome Plc is a British company that specializes in the discovery, development, manufacture, and sale of human healthcare products. The company is based in Greenford, UK. | Corporate Officer/Principal | - |
Oxagen Ltd.
Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
PFIZER, INC. | Health Technology |
Empresas privadas | 4 |
---|---|
Oxagen Ltd.
Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Health Technology |
Wellcome Plc
Wellcome Plc Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Wellcome Plc is a British company that specializes in the discovery, development, manufacture, and sale of human healthcare products. The company is based in Greenford, UK. | Commercial Services |
Orca Pharmaceuticals Ltd.
Orca Pharmaceuticals Ltd. BiotechnologyHealth Technology Orca Pharmaceuticals Ltd. operates as a biotechnology company that develops oral drugs for the treatment of chronic inflammatory diseases. It also develops oral drug for the treatment a spectrum of autoimmune diseases that includes psoriasis, ankylosing spondylitis and inflammatory bowel disease. The company was founded by Michael Hunter, Roy Pettipher, Dan Littman, and Jun R. Huh in 2012 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Atopix Therapeutics Ltd.
Atopix Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Atopix Therapeutics Ltd. develops medicines to treat atopic dermatitis and severe asthma. The firm also assess the safety and pharmacokinetic profile of its back-up molecule ATX2417 in a phase I study. The company was incorporated on October 10, 2012 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Roy Pettipher